X

Need an answer now?

Give us a call

Leave a message, we'll get back to you

Homepage > Reagents >

Get advice about BPS Bioscience

BPS Bioscience

products (2434) blog articles (20) webpages (2)

BPS Bioscience - tebu-bio

BPS Bioscience is leading producer of recombinant enzymes (wild-type and mutants), assay kits, substrates, and services for Drug Discovery. BPS Bioscience manufactures one of the largest selections of druggable targets (Acetyltransferases, HDACs, Histone Demethylases, Histone Methyltransferases, Kinases, Peptidases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases, Ubiquitin Enzymes...).

Recently, assays to investigate immuno checkpoint protein interactions in relation to immunotherapy drug discovery programs have been added to the portfolio of products and services (e.g. PD-1/PD-L1/PD-L2; B7-1/CD28, B7-1/CTLA4; BLTA/HVEM, CD47/SIRPα; GITR/GITRL; CD47:SIRPα; CD137:CD137L; CD40:CD40L; TIGIT/CD226 as well as the Trp catabolism pathway (IDO and TDO)).

Their expanding offer is available in Europe via tebu-bio. For advice on choosing your BPS products, get in touch with your local tebu-bio office.

Find your BPS Bioscience products below or contact your tebu-bio local office.

Split per category

Antibodies

Primary Antibodies

Assays & Kits

Cell Based Assays Functional Assays Support Products

Cells, Media & Fractions

Primary Cells Media & ECM Cell Lines Support Products

Genomics

Reporter Assays Enzymes Cloning Tools

Lab Consumables

Lipidomics

Molecules

Inhibitors & Activators Chemicals Labelling Substrates

Proteins & Peptides

Peptides Proteins

Others

20 blog articles

2 webpages

20 blog articles

Complete tool box to facilitate Immunotherapy research | tebu-bio's blog Facebook LinkedIn Twitter YouTube

3 novel PD-L1 post-translational modifications identified | tebu-bio's blog Facebook LinkedIn Twitter YouTube

IDO/TDO enzymatic pathway as an additional target for Cancer Drug Discovery | tebu-bio's blog Facebook LinkedIn Twitter YouTube

drug discovery | tebu-bio's blog - Part 3 Facebook LinkedIn Twitter YouTube

New Reporter cell lines for Drug discovery and Immunotherapy checkpoint research | tebu-bio's blog Facebook LinkedIn Twitter YouTube

Cell-based assay to discover new immuno-oncology treatments | tebu-bio's blog Facebook LinkedIn Twitter YouTube

HDACs: Active drug targets for Immunotherapy treatment | tebu-bio's blog Facebook LinkedIn Twitter YouTube

10 Human Immune Checkpoint biomarkers quantified simultaneously | tebu-bio's blog Facebook LinkedIn Twitter YouTube

Proteins with the High Purity (HiPTM) label make the difference | tebu-bio's blog Facebook LinkedIn Twitter YouTube

Versatile method to detect luciferase in reporter cell lines | tebu-bio's blog Facebook LinkedIn Twitter YouTube

PROTACs: A promising strategy in Drug Development | tebu-bio's blog Facebook LinkedIn Twitter YouTube

CAR T-Cell therapy: new hope for Immunotherapy and Cancer treatment | tebu-bio's blog Facebook LinkedIn Twitter YouTube

How to easily screen adenosine A2AR agonists and antagonists? | tebu-bio's blog Facebook LinkedIn Twitter YouTube

IL-17A pathway a key target for immunotherapies | tebu-bio's blog Facebook LinkedIn Twitter YouTube

Measure Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) | tebu-bio's blog Facebook LinkedIn Twitter YouTube

How to improve your reporter gene assays? | tebu-bio's blog Facebook LinkedIn Twitter YouTube

drug discovery | tebu-bio's blog Facebook LinkedIn Twitter YouTube

New Continued use immunotherapy cell line expressing recombinant PD-1 | tebu-bio's blog Facebook LinkedIn Twitter YouTube

Cell-based assay to discover new immuno-oncology treatments | tebu-bio's blog Facebook LinkedIn Twitter YouTube

ADCC | tebu-bio's blog Facebook LinkedIn Twitter YouTube

2 Webpages